BELFAST, UNITED KINGDOM, Diaceutics, a global leader in precision medicine, proudly announces that Susanne Munksted, Chief Precision Medicine Officer at Diaceutics plc, has been named as one of the esteemed honorees in this year's PharmaVoice 100. The annual list celebrates individuals who stand out as innovators, disruptors, and champions of diversity, equity, and inclusion within the life sciences industry.
With over two decades of experience in the pharmaceutical sector, Susanne Munksted has played a pivotal role in Diaceutics' Scientific & Advisory Services Team, overseeing global launches of companion diagnostic products and leveraging her extensive background in molecular pathology. As Chief Precision Medicine Officer, Susanne's primary mission is to help Diaceutics' clients recognize the critical relationship between testing and treatment, integrating precision medicine into corporate strategies and tactical plans.
Commenting on her recognition, Susanne Munksted said, "I am truly humbled and honoured to be recognized as a PharmaVoice 100 honoree. This prestigious accolade not only reflects my personal dedication to the industry but also serves as a testament to the incredible work being done by the entire Diaceutics team. It's a reminder that our efforts in advancing healthcare and improving patient lives are making a meaningful impact. This recognition fuels my passion and commitment to continue pushing the boundaries of innovation, and I am excited to be part of this dynamic community of inspiring individuals who share the same mission."
PharmaVoice 100 honorees are carefully selected from a pool of nominations submitted by readers and colleagues, and then assessed by the PharmaVoice team. This year's honorees encompass a diverse array of professionals, including standout executives, trailblazers, cancer care visionaries, clinical trial experts, patient advocates, entrepreneurs, tech innovators, rare disease champions, and brand and commercialization leaders.
Susanne Munksted's dedication to improving patient outcomes is evident in her tireless pursuit of solutions. Her leadership in championing the Clinical Practice Gaps Study, unveiled in October 2022, revealed the alarming statistic that 64% of patients are not receiving the treatment they require. Her unwavering commitment has not only raised awareness but also galvanized action across the industry.
Beyond her corporate role, Susanne actively engages with the global healthcare community by speaking at prestigious conferences, including World CDx, and as a featured speaker at the upcoming Precision Medicine Leaders Summit in Chicago on October 26-27. Her willingness to share knowledge and insights underscores her commitment to advancing precision medicine and addressing clinical practice gaps.
Peter Keeling, CEO of Diaceutics, extended his congratulations to Susanne, stating, "Our team is thrilled to see Susanne receive this well-deserved recognition as a PharmaVoice 100 honoree. Susanne's dedication, expertise, and relentless commitment to excellence have been instrumental in driving Diaceutics’ success. Her passion for innovation and her unwavering focus on improving patient outcomes have not only elevated our organization but have also positively impacted the entire industry. This nomination is a testament to her outstanding contributions and leadership. We are proud to have Susanne as a part of our team, and we congratulate her on this prestigious achievement."
Meagan Parrish, lead editor of PharmaVoice, remarked, "This industry is a ground-breaking one capable of changing the world through science and technology. These honorees inspire advancements by guiding their teams, supporting their patients, and propelling their organizations’ missions forward. We are excited to recognize their contributions through this annual list."
On October 25, Susanne Munksted will join fellow 2023 PharmaVoice 100 honorees during a virtual event. This event, hosted by award-winning journalists, will feature keynotes, panel discussions, and fireside chats, focusing on critical industry trends such as innovation, genetic medicine, research hotspots, the biotech market, clinical trial tech advancements, and more.
View Susanne's write-up alongside the other PharmaVoice 100 honorees here.
For media enquiries contact:
Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
Cathy Magovern Corporate Marketing & Communications Director | |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network®.
